1 – 20 of 25
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Feasibility of 177Lu activity quantification using a small portable CZT-based gamma-camera
(
- Contribution to journal › Article
-
Mark
Evaluation of superficial xenograft volume estimation by ultrasound and caliper against MRI in a longitudinal pre-clinical radiotherapeutic setting
(
- Contribution to journal › Article
- 2023
-
Mark
Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model
(
- Contribution to journal › Article
-
Mark
Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [177Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer
(
- Contribution to journal › Article
-
Mark
Investigation of a CZT-based hand-held gamma-camera for pre-clinical imaging of alpha-emitter 225Ac
2023) Annual Congress of the European Association of Nuclear Medicine In European Journal of Nuclear Medicine and Molecular Imaging 50(Suppl 1). p.129-129(
- Contribution to journal › Published meeting abstract
- 2022
-
Mark
Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
(
- Contribution to journal › Article
- 2021
-
Mark
Humanization, radiolabeling and biodistribution studies of an igg1-type antibody targeting uncomplexed psa for theranostic applications
(
- Contribution to journal › Article
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
(
- Contribution to journal › Article
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
(
- Contribution to journal › Article
- 2016
-
Mark
Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules
(
- Contribution to journal › Article
- 2015
-
Mark
Affibody molecules for PET imaging
2015) In Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine(
- Thesis › Doctoral thesis (compilation)
-
Mark
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
(
- Contribution to journal › Article
- 2014
-
Mark
Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo
(
- Contribution to journal › Article
-
Mark
Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates
(
- Contribution to journal › Article
-
Mark
Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde
(
- Contribution to journal › Article
-
Mark
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re
(
- Contribution to journal › Article
-
Mark
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule
(
- Contribution to journal › Article
-
Mark
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment
2014) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(11). p.8-1842(
- Contribution to journal › Article
- 2013
-
Mark
Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules : comparison with (111)In-labeled counterparts
(
- Contribution to journal › Article